Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.…
Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead
Alkermes (NASDAQ: ALKS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 2,050 employees.
The shares were at 44.94 USD on 20 November 2026, up 43.1% over 52 weeks. Its 52-week range is 27.00 USD to 55.67 USD: the price is 19.3% below the high and 66.4% above the low.
Its market capitalisation is 7.55B USD.
Alkermes reports return on equity of 13.3%, an operating margin of 11.5% and revenue up 21.8% year over year.
Its debt exceeds its cash by 815.62M USD, a debt-to-equity ratio of 0.04. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 19 analysts cover the stock, with an average rating of Buy; their mean price target of 57.74 USD is 28.5% above the current price. The next earnings report is expected on 24 February 2027.